Selective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis

Retrovirology

Volumn 5, Issue , 2008, Pages

  Young, Jessica ^a   Tang, Zhongwei ^a,b   Yu, Quan ^c   Yu, Dongyang ^a   Wu, Yuntao ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b SHANXI AGRICULTURAL UNIVERSITY   (China)

^c Advanced Vision Therapies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHROLYSIN O; BETA CYCLODEXTRIN DERIVATIVE; HEMOLYSIN; LENTIVIRUS VECTOR; REV PROTEIN; ANTHROLYSIN O, BACILLUS ANTHRACIS; BACTERIAL PROTEIN; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTOTOXICITY; MACROPHAGE; NONHUMAN; OLIGOMERIZATION; PROTEIN EXPRESSION; SUICIDE GENE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; CELL CULTURE; CELL DEATH; CYTOLOGY; DRUG EFFECT; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; PHYSIOLOGY; VIROLOGY;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

BACILLUS ANTHRACIS; BACTERIAL PROTEINS; BETA-CYCLODEXTRINS; CELL DEATH; CELLS, CULTURED; DNA, VIRAL; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HIV-1; HUMANS; LENTIVIRUS; MACROPHAGES; MEMBRANE GLYCOPROTEINS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES;

EID: 44349164639     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-5-36     Document Type: Article

References (64)

1. Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA Aschman DJ Holmberg SD Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 1998, 338l:853-60. 10.1056/ NEJM199803263381301
2. Torres RA Barr M Impact of combination therapy for HIV infection on inpatient census N Engl J Med 1997, 336l:1531-2. 10.1056/ NEJM199705223362118
3. Battegay M Nuesch R Hirschel B Kaufmann GR Immunological recovery and antiretroviral therapy in HIV-1 infection Lancet Infect Dis 2006, 6(5):280-7. 10.1016/S1473-3099(06)70463-7 16631548
4. Perelson AS Essunger P Cao Y Vesanen M Hurley A Saksela K Markowitz M Ho DD Decay characteristics of HIV-1-infected compartments during combination therapy Nature 1997, 387(6629):188-91. 10.1038/387188a0 9144290
5. Cavert W Notermans DW Staskus K Wietgrefe SW Zupancic M Gebhard K Henry K Zhang ZQ Mills R McDade H Schuwirth CM Goudsmit J Danner SA Haase AT Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection Science 1997, 276(5314):960-4. 10.1126/ science.276.5314.960 9139661
6. Finzi D Hermankova M Pierson T Carruth LM Buck C Chaisson RE Quinn TC Chadwick K Margolick J Brookmeyer R Gallant J Markowitz M Ho DD Richman DD Siliciano RF Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [see comments] Science 1997, 278(5341):1295-300. 10.1126/science.278.5341.1295 9360927
7. Chun TW Stuyver L Mizell SB Ehler LA Mican JA Baseler M Lloyd AL Nowak MA Fauci AS Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci USA 1997, 94:13193-7. 10.1073/pnas.94.24.13193 9371822 24285
8. Wong JK Hezareh M Gunthard HF Havlir DV Ignacio CC Spina CA Richman DD Recovery of replication-competent HIV despite prolonged suppression of plasma viremia [see comments] Science 1997, 278:1291-5. 10.1126/ science.278.5341.1291 9360926
9. Furtado MR Callaway DS Phair JP Kunstman KJ Stanton JL Macken CA Perelson AS Wolinsky SM Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy N Engl J Med 1999, 340:1614-22. 10.1056/ NEJM199905273402102 10341273
10. Crowe SM Sonza S HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: A further obstacle to eradication J Leukoc Biol 2000, 68:345-350. 10985250
11. Lambotte O Taoufik Y de Goer MG Wallon C Goujard C Delfraissy JF Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy J Acquir Immune Defic Syndr 2000, 23(2):114-9. 10737425
12. Davey RT Jr Bhat N Yoder C Chun TW Metcalf JA Dewar R Natarajan V Lempicki RA Adelsberger JW Miller KD Kovacs JA Polis MA Walker RE Falloon J Masur H Gee D Baseler M Dimitrov DS Fauci AS Lane HC HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression Proc Natl Acad Sci USA 1999, 96:15109-14. 10.1073/ pnas.96.26.15109 10611346 24781
13. Hatano H Vogel S Yoder C Metcalf JA Dewar R Davey RT Jr Polis MA Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression Aids 2000, 14:1357-63. 10.1097/00002030-200007070-00008 10930150
14. Finzi D Blankson J Siliciano JD Margolick JB Chadwick K Pierson T Smith K Lisziewicz J Lori F Flexner C Quinn TC Chaisson RE Rosenberg E Walker B Gange S Gallant J Siliciano RF Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat Med 1999, 5(5):512-517. 10229227 10.1038/8394
15. Ramratnam B Mittler JE Zhang L Boden D Hurley A Fang F Macken CA Perelson AS Markowitz M Ho DD The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy Nat Med 2000, 6(1):82-5. 10613829 10.1038/71577
16. Ramratnam B Ribeiro R He T Chung C Simon V Vanderhoeven J Hurley A Zhang L Perelson AS Ho DD Markowitz M Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication J Acquir Immune Defic Syndr 2004, 35(1):33-37. 10.1097/00126334-200401010-00004 14707789
17. Zhu T Muthui D Holte S Nickle D Feng F Brodie S Hwangbo Y Mullins JI Corey L Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy J Virol 2002, 76:707-716. 10.1128/JVI.76.2.707-716.2002 11752161 136806
18. Chun TW Davey RT Jr Ostrowski M Shawn Justement J Engel D Mullins JI Fauci AS Relationship between pre-existing viral reservoirs and the reemergence of plasma viremia after discontinuation of highly active antiretroviral therapy Nat Med 2000, 6:757-761. 10.1038/77481 10888923
19. Dybul M Daucher M Jensen MA Hallahan CW Chun TW Belson M Hidalgo B Nickle DC Yoder C Metcalf JA Davey RT Ehler L Kress-Rock D Nies-Kraske E Liu S Mullins JI Fauci AS Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy J Virol 2003, 77:3229-3237. 10.1128/ JVI.77.5.3229-3237.2003 12584346 149739
20. Crowe S Zhu T Muller WA The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection J Leukoc Biol 2003, 74:635-641. 10.1189/jlb.0503204 12960232
21. Williams KC Corey S Westmoreland SV Pauley D Knight H deBakker C Alvarez X Lackner AA Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: Implications for the neuropathogenesis of AIDS J Exp Med 2001, 193:905-915. 10.1084/jem.193.8.905 11304551 2193403
22. Igarashi T Brown CR Endo Y Buckler-White A Plishka R Bischofberger N Hirsch V Martin MA Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans Proc Natl Acad Sci USA 2001, 98:658-663. 10.1073/pnas.021551798 11136236 14644
23. Crowe SM McGrath MS Elbeik T Kirihara J Mills J Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus J Med Virol 1989, 29:176-180. 10.1002/jmv.1890290306 2533247
24. Perno CF Aquaro S Rosenwirth B Balestra E Peichl P Billich A Villani N Calio R In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages J Leukoc Biol 1994, 56(3):381-386. 8083612
25. Sonza S Mutimer HP Oelrichs R Jardine D Harvey K Dunne A Purcell DF Birch C Crowe SM Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy Aids 2001, 15:17-22. 10.1097/00002030-200101050-00005 11192864
26. Stellbrink HJ Hufert FT Tenner-Racz K Lauer J Schneider C Albrecht H Racz P van Lunzen J Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2 Antivir Ther 1998, 3(4):209-214. 10682140
27. Chun TW Engel D Mizell SB Hallahan CW Fischette M Park S Davey RT Jr Dybul M Kovacs JA Metcalf JA Mican JM Berrey MM Corey L Lane HC Fauci AS Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active antiretroviral therapy [see comments] Nat Med 1999, 5:651-655. 10.1038/9498 10371503
28. Lafeuillade A Poggi C Chadapaud S Hittinger G Chouraqui M Pisapia M Delbeke E Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission J Acquir Immune Defic Syndr 2001, 26(1):44-55. 11176268
29. Dybul M Hidalgo B Chun TW Belson M Migueles SA Justement JS Herpin B Perry C Hallahan CW Davey RT Metcalf JA Connors M Fauci AS Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection J Infect Dis 2002, 185:61-68. 10.1086/ 338123 11756982
30. Lehrman G Hogue IB Palmer S Jennings C Spina CA Wiegand A Landay AL Coombs RW Richman DD Mellors JW Coffin JM Bosch RJ Margolis DM Depletion of latent HIV-1 infection in vivo: A proof-of-concept study Lancet 2005, 366:549-555. 10.1016/S0140-6736(05)67098-5 16099290 1894952
31. Siliciano JD Lai J Callender M Pitt E Zhang H Margolick JB Gallant JE Cofrancesco J Jr Moore RD Gange SJ Siliciano RF Stability of the latent reservoir for HIV-1 in patients receiving valproic acid J Infect Dis 2007, 195:833-836. 10.1086/511823 17299713
32. Chaudhary VK Mizukami T Fuerst TR FitzGerald DJ Moss B Pastan I Berger EA Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein Nature 1988, 335:369-372. 10.1038/335369a0 2843774
33. Turner LS Tsygankov AY Henderson EE StpC-based gene therapy targeting latent reservoirs of HIV-1 Antiviral Res 2006, 72:233-241. 10.1016/ j.antiviral.2006.06.010 16891001
34. Wu Y Beddall MH Marsh JW Rev-dependent lentiviral expression vector Retrovirology 2007, 4:12. 10.1186/1742-4690-4-12 17286866 1797186
35. Malim MH Hauber J Le SY Maizel JV Cullen BR The HIV-1 rev transactivator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA Nature 1989, 338:254-257. 10.1038/338254a0 2784194
36. Wu Y Beddall MH Marsh JW Rev-dependent indicator T cell line Current HIV Research 2007, 5(4):395-403. 17627502 2366165
37. Gilbert RJ Rossjohn J Parker MW Tweten RK Morgan PJ Mitchell TJ Errington N Rowe AJ Andrew PW Byron O Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae J Mol Biol 1998, 284:1223-1237. 10.1006/jmbi.1998.2258 9837740
38. Shatursky O Heuck AP Shepard LA Rossjohn J Parker MW Johnson AE Tweten RK The mechanism of membrane insertion for a cholesteroldependent cytolysin: A novel paradigm for pore-forming toxins Cell 1999, 99:293-299. 10.1016/S0092-8674(00)81660-8 10555145
39. Decatur AL Portnoy DA A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. [see comment] Science 2000, 290:992-995. 10.1126/science.290.5493.992 11062133
40. Provoda CJ Stier EM Lee KD Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin J Biol Chem 2003, 278:35102-35108. 10.1074/jbc.M305411200 12832408
41. Naldini L Blomer U Gallay P Ory D Mulligan R Gage FH Verma IM Trono D In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 1996, 272:263-267. 10.1126/ science.272.5259.263 8602510
42. Shannon JG Ross CL Koehler TM Rest RF Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin Infection & Immunity 2003, 71:3183-3189. 10.1128/IAI.71.6.3183-3189.2003
43. He J Choe S Walker R Di Marzio P Morgan DO Landau NR Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity J Virol 1995, 69(11):6705-6711. 7474080 189580
44. Englund G Theodore TS Freed EO Engleman A Martin MA Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1 J Virol 1995, 69(5):3216-3219. 189028 7707554
45. Karginov VA Nestorovich EM Moayeri M Leppla SH Bezrukov SM Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design Proc Natl Acad Sci USA 2005, 102:15075-15080. 10.1073/pnas.0507488102 16214885 1257733
46. Karginov VA Yohannes A Robinson TM Fahmi NE Alibek K Hecht SM Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin Bioorg Med Chem 2006, 14:33-40. 10.1016/j.bmc.2005.07.054 16169738
47. Yamaizumi M Mekada E Uchida T Okada Y One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell Cell 1978, 15:245-250. 10.1016/0092-8674(78)90099-5 699044
48. Bhakdi S Tranum-Jensen J Alpha-toxin of Staphylococcus aureus Microbiol Rev 1991, 55(4):733-751. 1779933 372845
49. Mosser EM Rest RF The Bacillus anthracis cholesterol-dependent cytolysin, Anthrolysin O, kills human neutrophils, monocytes and macrophages BMC Microbiol 2006, 6:56. 10.1186/1471-2180-6-56 16790055 1550246
50. Perez VL Rowe T Justement JS Butera ST June CH Folks TM An HIV-1-infected T cell clone defective in IL-2 production and Ca2+ mobilization after CD3 stimulation J Immun 1991, 147(9):3145-3148. 1833465
51. Cheng-Mayer C Liu R Landau NR Stamatatos L Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor J Virol 1997, 71(2):1657-1661. 8995695 191226
52. Lassen K Han Y Zhou Y Siliciano J Siliciano RF The multifactorial nature of HIV-1 latency Trends Mol Med 2004, 10:525-531. 10.1016/ j.molmed.2004.09.006 15519278
53. Poeschla E Corbeau P Wong-Staal F Development of HIV vectors for anti-HIV gene therapy Proc Natl Acad Sci USA 1996, 93:11395-11399. 10.1073/pnas.93.21.11395 8876146 38068
54. Zhang J Temin HM Rate and mechanism of nonhomologous recombination during a single cycle of retroviral replication Science 1993, 259:234-238. 10.1126/science.8421784 8421784
55. Zhang J Temin HM 3' junctions of oncogene-virus sequences and the mechanisms for formation of highly oncogenic retroviruses J Virol 1993, 67(4):1747-1751. 240211 8445707
56. Negroni M Buc H Retroviral recombination: What drives the switch? Nat Rev Mol Cell Biol 2001, 2:151-155. 10.1038/35052098 11252957
57. Martin GS Lee WH Duesberg PH Generation of nondefective Rous sarcoma virus by asymmetric recombination between deletion mutants J Virol 1980, 36(2):591-594. 6253679 353678
58. Wu Y Marsh JW Early transcription from nonintegrated DNA in human immunodeficiency virus infection J Virol 2003, 77:10376-10382. 10.1128/ JVI.77.19.10376-10382.2003 12970422 228496
59. Kelly J Beddall MH Yu D Iyer SR Marsh JW Wu Y Human macrophages support persistent transcription from unintegrated HIV-1 DNA Virology 2008, 372(2):300-312. 2276161 18054979 10.1016/j.virol.2007.11.007
60. Yanez-Munoz RJ Balaggan KS MacNeil A Howe SJ Schmidt M Smith AJ Buch P MacLaren RE Anderson PN Barker SE Duran Y Bartholomae C von Kalle C Heckenlively JR Kinnon C Ali RR Thrasher AJ Effective gene therapy with nonintegrating lentiviral vectors Nat Med 2006, 12:348-353. 10.1038/ nm1365 16491086
61. Saenz DT Loewen N Peretz M Whitwam T Barraza R Howell KG Holmes JM Good M Poeschla EM Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: Analysis with class I integrase mutants J Virol 2004, 78:2906-2920. 10.1128/JVI.78.6.2906-2920.2004 14990709 353756
62. Philippe S Sarkis C Barkats M Mammeri H Ladroue C Petit C Mallet J Serguera C Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo Proc Natl Acad Sci USA 2006, 103:17684-17689. 10.1073/pnas.0606197103 17095605 1693807
63. Endres MJ Jaffer S Haggarty B Turner JD Doranz BJ O'Brien PJ Kolson DL Hoxie JA Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes Science 1997, 278:1462-1464. 10.1126/ science.278.5342.1462 9367958
64. Levine BL Humeau LM Boyer J MacGregor RR Rebello T Lu X Binder GK Slepushkin V Lemiale F Mascola JR Bushman FD Dropulic B June CH Gene transfer in humans using a conditionally replicating lentiviral vector Proc Natl Acad Sci USA 2006, 103:17372-17377. 10.1073/pnas.0608138103 17090675 1635018